Wednesday 17 May
08:00
08:00 - 08:45 Sponsored breakfast meeting II
Please view more detailed information about this program item under the tab sponsored sessions.
08:00
08:00 - 08:45 [CLOSED MEETING] BORNEO Group
08:00 - 08:45 Educational Session 2
08:00
Immunotherapy for NB - GD2, CAR-T and all the other options
John Anderson, UK
08:20
Tumor microenvironment in NB
Yves Declerck, United States
09:00 - 10:00 Plenary session 5: Immune therapy
Moderators: Julie Park, United States & John Anderson, United Kingdom
09:00
PS5.1 Bispecific SNIPER Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma
Paul Sondel, United States
09:15
PS5.2 Integrative analysis of neuroblastoma by single‐cell RNA sequencing identifies the NECTIN2‐TIGIT axis as a target for immunotherapy
Judith Wienke, the Netherlands
09:30
PS5.3 Multi-antigen targeting of neuroblastoma with CAR T-cells secreting bispecific innate immune cell engagers
Guillem Pascual-Pasto, United States
09:45
PS5.4 A novel B7H3 targeting chimeric antigen receptor regulated by an IMiD drug sensitive degron tag, optimised for neuroblastoma immunotherapy
Sophie Munnings-Tomes, UK
10:00 - 10:50 Parallel session 11: Immune Therapy
Moderators: Juliet Gray, United Kingdom & Annette Künkele, Germany
10:00
O11.1 Depletion of CD11b+ myeloid cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody dinutuximab beta
Leon von Lojewski, Germany
10:12
O11.2 T cell mediated killing of neuroblastoma is inhibited by secreted midkine
Josephine Strijker, the Netherlands
10:24
O11.3 Allogeneic CAR T cells targeting GD2 for Treatment of Relapsed/Refractory High-Risk Neuroblastoma
Francesca del Bufalo, Italy
10:36
O11.4 Library-based Discovery of Peptide-centric CAR T Cells for Neuroblastoma (NB)
Quinlen Marshall, United States
10:00 - 10:50 Parallel session 12: Stem cell derived models to study NB
Moderators: Katleen De Preter, Belgium & Frank Speleman, Belgium
10:00
O12.1 Identification of genetic drivers of relapse in MYCN driven neuroblastoma
Miller Huang, United States
10:12
O12.2 Single-cell transcriptome and epigenome analysis in a stem cell model reveal developmental impact of neuroblastoma-associated chromosomal aberrations
Florian Halbritter, Austria
10:24
O12.3 Maintenance of pluripotency in the entire ectoderm enables neural crest formation – insights from normal development to help understand neuroblastoma
Laura Kerosuo, United States
10:36
O12.4 Modelling neuroblastoma using germline ALK-R1275Q mutant patient-derived induced pluripotent stem cells
Mingzhi Liu, Sweden
10:50
10:50 - 11:20 Coffee break
11:20 - 12:25 Parallel session 13: Precision therapy: Novel combinations
Moderators: Godfrey Chan, Hong Kong & Emmy Dolman, Australia
11:20
O13.1 Combining venetoclax with lorlatinib leads to complete responses in multiple neuroblastoma models with high BCL-2 expression and ALK mutation.
Lindy Vernooij, the Netherlands
11:32
O13.2 Combining Notch blockade with High-dose radiation therapy (HDRT) and immunotherapy (IO) results in a synergistic growth inhibition of NB tumors.
Debarshi Banerjee, United States
11:44
O13.3 The CDK7/CDK9 and CKIα co-inhibitor exerts efficacious anticancer effects against TERT gene-rearranged neuroblastoma
Tao Liu, Australia
11:56
O13.4 Dual-selective pharmacotherapy achieves profound and lasting tumor growth suppression in experimental models of MYCN-amplified neuroblastoma
Michael Chorny, United States
11:20 - 12:25 Parallel session 14: Clinical trials for relapsed neuroblastoma
Moderators: Pablo Berlanga, France & Lucas Moreno, Spain
11:20
O14.1 Circulating adrenergic neuroblastoma mRNAs predict outcomes in children with relapsed and refractory neuroblastoma; a BEACON-Neuroblastoma biomarker study
Sue Burchill, UK
11:32
O14.2 Significantly improved PFS in relapsed/refractory neuroblastoma adding molecular targeted drugs to Irinotecan/Temozolomide: Results of a randomized phase II trial (RIST)
Selim Corbacioglu, Germany
11:44
O14.3 Phase I Study of 131I-MIBG with Dinutuximab +/- Vorinostat for Patients with Relapsed or Refractory Neuroblastoma (NANT 2017-01)
Thomas Cash, United States
11:56
O14.4 Norepinephrine transporter and vesicular monoamine transporter-2 tumor expression as a predictor of response to 131I-MIBG in patients with relapsed/refractory neuroblastoma
Vandana Batra, United States
12:08
O14.5 Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase I trial results and insights into mechanisms of resistance through tracking of serial circulating tumor DNA
Yael Mossé, United States
12:25 - 12:40 Rapid Fire session 2A
Moderator: Ellen Westerhout, the Netherlands
12:25
P215 Peptide-centric CAR T cell therapy targeting the tumor-associated antigen PRAME
Erin Runbeck, United States
12:26
P208 IgA3.0 ch14.18 antibodies are effective in preclinical neuroblastoma models without inducing neuropathic pain
Marjolein Stip, the Netherlands
12:27
P212 Antigen-driven cytokine expression systems to enhance the function and overcome challenges of CAR T cell therapy in neuroblastoma
Reona Okada, United States
12:28
P213 Desensitizing the Autonomic Nervous System to mitigate anti-GD2 Monoclonal Antibody Side Effects
Jaume Mora, Spain
12:29
P209 Best of two worlds: Engineering NKT-cells to generate an alternative adaptive cell therapy strategy against neuroblastoma
Annelisa Cornel, the Netherlands
12:30
P211 Immunomodulatory effect of the MEK pathway inhibitor enhanced the efficacy of GD2-CAR-T cell therapy against neuroblastoma
Akimasa Tomida, Japan
12:31
P210 GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma
Kristopher Bosse, United States
12:33
P130 A zebrafish larvae xenograft model for high-throughput drug testing and precision medicine in neuroblastoma
Joshua Robert Goulding, Belgium
12:34
P129 Pseudometastatic allografting of TH-MYCN neuroblastoma cells with loss of p53 function provides an efficient syngeneic model of advanced-stage, high-risk disease
Garrett Brodeur, United States
12:35
P128 Unbiased high-throughput screening and preclinical testing in PDX models identifies synergistic combinations with the BCL2 inhibitor venetoclax
Jamie Fletcher, Australia
12:40
12:40 - 13:40 Lunch & Poster Session Group C
Posters with reference P192 until P270
14:00
Social program
Based on pre registration